Akorn, Inc. and CSL Biotherapies Sign a Specialty Distributor Agreement for Afluria(R) (Flu Vaccine)

BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ: AKRX) a specialty pharmaceutical company, and CSL Biotherapies, Inc., a subsidiary of CSL Limited, have entered into a Specialty Distributor Agreement for Afluria®, a seasonal influenza vaccine. Akorn will market and distribute two presentations of Afluria®: pre-filled syringes without latex or thimerosal, and preserved multi-dose vials. Akorn will immediately begin pre-booking sales for the 2008 flu season. According to recent IMS sales data, the current flu vaccine market size in the U.S. and Puerto Rico is approximately $800 million. Arthur S. Przybyl, Akorn’s President and Chief Executive Officer stated, “We are extremely excited about our Distributor relationship with CSL Biotherapies, a preeminent global manufacturer of vaccines. For Akorn, Afluria® represents the second product in our vaccine portfolio, Tetanus Diphtheria Vaccine being the first, and allows us to leverage the sales capabilities of our Vaccine Representatives. Currently, Akorn has approximately 50 field and inside sale representatives marketing our Tetanus Diphtheria Vaccine to office based physicians, hospitals, public health facilities, occupational health businesses and government institutions.”

Back to news